Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
819people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
IDegLira
degludec
Probably lowered long-term blood sugar−6.91
Probably lowered severe or blood glucose-confirmed hypoglycaemia−52%
randomisedThe trial randomly assignedassigned by chance
IDegLira
liraglutide
Probably lowered long-term blood sugar−5.30
Probably raised severe or blood glucose-confirmed hypoglycaemia38×
randomisedthe abstract, start to end
… estimated treatment differences were -6.91 mmol/mol (95% confidence interval [CI] -8.18; -5.64) and -5.30 mmol/mol (95% CI -6.58; -4.03), …
… were lower versus degludec (rate ratio 0.48 [95% CI 0.35; 0.68]; P < .0001), but higher versus liraglutide (rate ratio 37.58 [95% CI 19.80; 71.31]; …
← favours treatmentfavours comparator →
could be chanceGlycated haemoglobin (HbA1c)IDegLira vs degludec
−6.91−8.18 to −5.64
Glycated haemoglobin (HbA1c)IDegLira vs liraglutide
−5.30−6.58 to −4.03
Rates of severe or blood glucose-confirmed hypoglycaemiaIDegLira vs degludec
IRR 0.480.35–0.68
Rates of severe or blood glucose-confirmed hypoglycaemiaIDegLira vs liraglutide
IRR 37.5819.8–71.3
InsulinGlycemic controlAdverse events & safety
1 / 4